AccuSift provides high‑performance methotrexate competitive assay pairings, characterized by exceptional batch‑to‑batch consistency and optimized for IVD kit development (Lateral Flow, Chemiluminescence, ELISA, POCT). These pairings offer high affinity and specificity, facilitating rapid detection.Methotrexate (MTX) is an antifolate antineoplastic agent that competitively inhibits the activity of dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate. High‑dose MTX significantly increases plasma concentrations, enabling it to cross the blood‑brain barrier and reach poorly perfused solid tumors via passive diffusion. Currently, HD‑MTX is widely used in acute lymphoblastic leukemia, osteosarcoma, lymphoma, and other malignancies.While HD‑MTX kills tumor cells, it also causes severe damage to multiple organ systems. Due to considerable inter‑ and intra‑individual pharmacokinetic variability, a narrow therapeutic index, and high toxicity, it often induces adverse effects (e.g., myelosuppression, cardiac injury, hepatic and renal impairment, mucocutaneous lesions, gastrointestinal reactions) that can be fatal in severe cases. Therefore, timely and appropriate leucovorin rescue, along with monitoring MTX plasma concentration and its duration, is critical.Performance Characteristics:
Sensitivity: ELISA IC50: 0.2 ppb
Source: Mouse Monoclonal Antibody
Recommended Pairing: (Coating) / (Labeling)
Storage: Long‑term storage at ≤ –20°C; short‑term storage at 2–8°C. Shipped on ice packs.
WeChat
